HRMY
Harmony Biosciences Holdings
NASDAQ: HRMY · HEALTHCARE · BIOTECHNOLOGY
$41.52
+1.02% today
Updated 2026-09-11
Market cap
$2.42B
P/E ratio
13.47
P/S ratio
2.53x
EPS (TTM)
$3.09
Dividend yield
—
52W range
$26 – $43
Volume
0.8M
Harmony Biosciences Holdings (HRMY) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$41.52
12-Month target
$22.07
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.3B | $0.4B | $0.6B | $0.7B | $0.9B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 13.47x (capped 25x) · Margin: 18.90%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.